Dr. Wolfgang Barth joined AC Immune from TRIN-Pharma, where he was Head of Development and advanced an anticancer drug through the pre-clinical into the clinical phase. Before this, he was at Bayer Healthcare, where he was the responsible project leader of numerous preclinical and clinical development projects. The most important project was the development of the PDE5 inhibitor Levitra which he led from the start of preclinical development until market launch. Wolfgang Barth holds a PhD in Chemistry from the University of Marburg, Germany and received a NATO stipend for a postdoctoral staff position at the Ohio State University.
numerous preclinical and clinical development projects